Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Plus Therapeutics Inc (PSTV)

Plus Therapeutics Inc (PSTV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,338
  • Shares Outstanding, K 17,000
  • Annual Sales, $ 5,820 K
  • Annual Income, $ -12,980 K
  • EBIT $ -15 M
  • EBITDA $ -14 M
  • 60-Month Beta 0.64
  • Price/Sales 1.02
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.40
  • Most Recent Earnings $-0.56 on 05/30/25
  • Next Earnings Date 06/04/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.13
  • Prior Year -0.71
  • Growth Rate Est. (year over year) +83.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2600 +20.77%
on 05/20/25
0.7458 -57.90%
on 05/14/25
-0.3840 (-55.01%)
since 05/13/25
3-Month
0.2600 +20.77%
on 05/20/25
2.0800 -84.90%
on 03/20/25
-0.4361 (-58.14%)
since 03/13/25
52-Week
0.2400 +30.83%
on 03/04/25
2.3099 -86.41%
on 03/07/25
-1.8160 (-85.26%)
since 06/13/24

Most Recent Stories

More News
Plus: Q1 Earnings Snapshot

Plus: Q1 Earnings Snapshot

PSTV : 0.3140 (-10.29%)
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

PSTV : 0.3140 (-10.29%)
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

PSTV : 0.3140 (-10.29%)
Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

PSTV : 0.3140 (-10.29%)
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

PSTV : 0.3140 (-10.29%)
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

For Immediate ReleaseChicago, IL – April 24, 2025 – Today, Zacks Equity Research discusses Aurinia Pharmaceuticals AUPH, Heron Therapeutics HRTX, Esperion Therapeutics ESPR, Pyxis Oncology PYXS and...

ESPR : 1.1700 (-2.50%)
PSTV : 0.3140 (-10.29%)
PYXS : 1.2000 (-1.64%)
AUPH : 8.18 (-0.61%)
HRTX : 1.9300 (-3.98%)
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

PSTV : 0.3140 (-10.29%)
Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

PSTV : 0.3140 (-10.29%)
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

PSTV : 0.3140 (-10.29%)
Plus Therapeutics Introduces REYOBIQâ„¢, FDA-Accepted Proprietary Name for Lead Drug Candidate

PSTV : 0.3140 (-10.29%)

Business Summary

Plus Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing treatments for cancer and other diseases primarily in the United States. The company's product candidate consists of DocePLUS which are in clinical stage. Plus Therapeutics Inc., formerly known as Cytori Therapeutics...

See More

Key Turning Points

3rd Resistance Point 0.3588
2nd Resistance Point 0.3487
1st Resistance Point 0.3314
Last Price 0.3140
1st Support Level 0.3040
2nd Support Level 0.2939
3rd Support Level 0.2766

See More

52-Week High 2.3099
Fibonacci 61.8% 1.5192
Fibonacci 50% 1.2750
Fibonacci 38.2% 1.0307
Last Price 0.3140
52-Week Low 0.2400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar